Till startsida
To content Read more about how we use cookies on gu.se

Immunometabolism Group

Principal Investigator: John-Olov Jansson

Our long-term aim is to study the interactions between the immune system and metabolic function. We were first to show in 2002 and 2006 that lack of biological effects of endogenous interleukin-6 (IL-6; Wallenius V et al 2002, Nat Med 8:75-79; 885 citations in Google Scholar) or IL-1 (Garcia M et al Diabetes 55:1205-1213) causes mature onset obesity in mice, probably by increasing energy expenditure at the level of the central nervous system.

In 2013, we found that brainstem glucagon-like peptide-1 (GLP-1) exerts its well known and clinically relevant anti-obesity effect by increasing the expression of IL-6 and IL-1 in the brain (Shirazi R et al 2013, Proc Natl Acad Sci, USA 110: 16199-16204). Our aim for the next 3-5 years is to investigate how and where in the brain the chain of events GLP-1 →  IL-6 (& IL-1) → anti-obesity are exerted.

Understanding the mechanism of action of a successful obesity treatment like GLP-1 analogues is likely to result in new and more refined treatments of obesity.

Photo of John-Olov Jansson

John-Olov Jansson

Principal Investigator, Professor

PubMed - Publications
Google Scholar - Publications

Tel: +46 (0)31-786 3526
Mobile: +46 (0)739-01 11 22
E-mail: joj@medic.gu.se
Visiting and postal addresses

Page Manager: Annie Sundling|Last update: 8/11/2015

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?